How Women in Search of Suitable Contraceptive Methods can Remedy the Lack of Counseling and Circumvent Untrustworthy Information Disseminated by Various Media

Kurt Kraetschmer MD, PhD*
Austrian American Medical Research Institute, Austria

Abstract

Background: The urgent need for appropriate counseling regarding contraceptive options is a well-known phenomenon in the clinical practice. Recent events show that this need has not yet been met. On the background of this evidence, new avenues are explored to enable women to remedy the lack of adequate counseling and circumvent untrustworthy information disseminated by various media.

Material and Method: Material used comprises publications in leading medical journals with the highest impact factors, publications by manufacturers and by the internationally most influential health agencies. This material is subjected to a methodological analysis which is guided by the bioethical principles of nil nocere and informed consent.

*Corresponding Author: Kurt Kraetschmer MD, PhD, Austrian American Medical Research Institute, Austria, Email: kurt.kraetschmer@aon.at

The Table below (Table 1) Displays this Synoptic Contraception Overview

| Method                                      | Safety (no harm in the sense of “nil nocere”) | Efficacy [Perfect-Typical use] | Satisfaction [% women continuing after one year] | Convenience | Cost & Specifications |
|---------------------------------------------|-----------------------------------------------|-------------------------------|-----------------------------------------------|--------------|----------------------|
| Symptothermal (measure body temperature and observe cervical mucus) | High                                           | 0.4-24                        | ? High                                       |              | No cost. Cervix palpated has soft consistency and is open. |
| Ovulation (based on cervical mucus)         | High                                           | 3-24                          | ? High                                       |              | No cost. Observe cervical mucus (“spinnbarkeit” indicates fertile period). |
| TwoDay (based on cervical mucus) Fertility not to be assumed after 2 | High                                           | 4-24                          | ? High                                       |              | No cost. Fertile days to be assumed when cervical mucus is present (watch color and consistency). |
How Women in Search of Suitable Contraceptive Methods can Remedy the Lack of Counseling and Circumvent Untrustworthy Information Disseminated by Various Media

| Contraceptive Method | Effectiveness | Description |
|----------------------|--------------|-------------|
| consecutive “dry” days (or absence of secretion). | High | 5-24 | No cost. Fertile period usually days 8-19 of each 26-32 day cycle. |
| Standard Days Method (SDM) – based on calendar to track fertile period. | High | 1-25 | No cost. Does not predict end of fertile period, but conception is unlikely from the 4th day following rise of temperature (until next period). |
| Basal Body Temperature (BBT) Fertile period has passed when body temperature has risen (by 0.2-0.5°C) and remained such for 3 days. | High | 9-25 | No cost. Check calendar to find shortest cycle and subtract 18: this is the estimated FIRST fertile day. Find longest cycle and subtract 11: this is the estimated LAST last fertile day. Caution with drugs such as NSAID, antibiotics, anxiolytics, anti-depressants, and others (consult physician). |
| Calendar (rhythm) method Monitor menstrual cycle for at least 6 months by using calendar. | High | 4-22 | 46% | Semen must be discharged outside the vagina. Effective in preventing ovulation as long as monthly bleeding has not yet resumed. |
| Withdrawal (coitus INTERRUPTUS) | High | 2-18 | 43% | Moderate | Low cost. Protects against sexually transmitted diseases (STD) including HIV. |
| Lactational Amenorrhea (LAM) Requires breastfeeding day and night of infant less than 6 months old. | High | 0.05-0.05 | 84% | Moderate | High cost. Has to be implanted by clinician. |
| Male condoms Latex allergy possible. | Moderate | 0.2-0.2 | 80% | Moderate | High cost. Prevents contact between sperm and egg by thickening cervical mucus. Amenorrhea common. |
| Mirena (LNG) Intrauterine device (IUD) (T-shaped plastic device inserted into the uterus; releases continuously small amounts of levonorgestrel). | Moderate | 0.6-0.8 | 78% | Moderate | High cost. Copper component damages sperms. |
| ParaGard (copper IUD) | Moderate | 0.2-6 | 56% | Moderate | High cost. |
| Depo-Provera | Moderate | 0.05-0.05 | 84% | Moderate | High cost. |

ARC Journal of Gynecology and Obstetrics
How Women in Search of Suitable Contraceptive Methods can Remedy the Lack of Counseling and Circumvent Untrustworthy Information Disseminated by Various Media

| Method                                                                 | Effectiveness | Side Effects | Duration | Notes                                                                 |
|-----------------------------------------------------------------------|---------------|--------------|----------|-----------------------------------------------------------------------|
| Combined oral contraceptives (COCs) = “the pill”                      | Moderate      | 0.3-9        | 67%      | Moderate cost. Contains estrogen and progestogen.                     |
| Progestogen-only pill (POP) or “minipill”                             | Moderate      | 1-3(10)      | 67%      | Moderate cost. Thickens cervical mucus and prevents ovulation.        |
| Evra patch                                                            | Moderate      | 0.3-9        | 67%      | High cost.                                                            |
| NuvaRing                                                              | Moderate      | 0.3-9        | 67%      | High cost.                                                            |
| Combined contraceptive patch and combined contraceptive vaginal ring (CVR) | Moderate      | 1-8(?)       | ?        | Low                                                                   |
| Monthly injectables or combined injectable contraceptives (CIC)       | Moderate      | Irregular    | 1-3      | ? Low                                                                 |
| Progestogen-only injectables                                          | Moderate      | Irregular    | 1-3      | ? Low                                                                 |
| Diaphragm Must be used for each coitus                                | Moderate      | 6-12         | 57%      | Low                                                                   |
| Emergency Contraception (EC) Pills ulipristal acetate 30 mg or levonorgestrel 1.5 mg should be taken twice to prevent pregnancy up to 5 days subsequent to coitus. | Moderate - Low | 1-15        | ? High | Moderate cost. Instead of pill IUD (copper or levonorgestrel) can be inserted. |
| Male sterilization (vasectomy)                                        | Moderate      | <1 (after 3 months semen evaluation). 2-3 (without semen evaluation). | 100%      | High cost. Permanent contraception due to cutting vas deferens tubes (which transport sperm from testicles). |
| Female sterilization (tubal ligation) Permanent contraception (due to blocking or cutting fallopian tubes). | Low         | 0.5-0.5      | 100%      | High cost. Surgery required.                                          |
| Sterilization through creation of scar tissue (ESSURE)               | Very low      | ?            | ? Low    | Device has been withdrawn from the market in several countries, including the U.S. |
| Sponge                                                               | Moderate      | 20-24        | 36%      | Moderate cost. Must be used for each coitus.                         |

ARC Journal of Gynecology and Obstetrics
How Women in Search of Suitable Contraceptive Methods can Remedy the Lack of Counseling and Circumvent Untrustworthy Information Disseminated by Various Media

| contraception method | type | age range | complication rate | cost |
|----------------------|------|-----------|-------------------|------|
| Spermicides          | Moderate | 18-28 | 42% High | Moderate cost |

1. DISCUSSION

In 2018, a spokesman of the FDA openly admitted the existence of a problem that has been plaguing the clinical practice for many years, namely lack of adequate counseling for women who are in search of the personally must suitable method for family planning, birth control or contraception. In conjunction with a device for permanent contraception which had caused severe harm to thousands of women worldwide it has been noted that women did not receive adequate counseling prior to the implementation of a contraceptive method. This lack was the more surprising as the FDA had already earlier restricted implantation of the device to those physicians who had signed a document attesting that they had provided counseling for the women receiving the device: “Despite previous efforts to alert women to the potential complications of Essure, we know that some patients still aren’t receiving this important information,” said FDA Commissioner Scott Gottlieb, in a statement. “That is simply unacceptable.”[1] In criticizing a serious lack of counseling, the FDA admits that patients’ right of self-decision according to the principle of informed consent had been seriously violated. [2] The problem of denying the right of women to self-decision is unfortunately not a recent phenomenon, as can be seen from a study focusing on self-decision in conjunction with contraceptive methods published in Germany. [3]

The fatal consequences of the lack of counseling have been reported by news media around the world. In the US, the press drew attention to adverse events caused by the device and the ensuing legal ramifications: “It has been the subject of an estimated 16,000 lawsuits or claims filed by women who reported severe injuries, including perforation of the uterus and the fallopian tubes. Several deaths, including of a few infants, have also been attributed to the device or to complications from it.”[1]

In Australia, the Therapeutic Goods Administration (TGA) had issued a hazard alert earlier, and the company apparently felt compelled to recall its product already in 2017. According to Australian media, this alert was prompted by reports about severe harm experienced by the users: “The reports have included changes in menstrual bleeding, unintended pregnancy, chronic pain, perforation, migration of the device, and allergy/hypersensitivity or immune-type reactions. Surgery, including hysterectomy, was required in some instances to remove the device,” the TGA said. “[4]

What came as a surprise to consumers in the US was the FDA’s emphasis on the safety of the device: “Bayer announced that they will no longer sell or distribute Essure in the U.S. after December 31, 2018, for business reasons. This information does not change the FDA’s understanding of the safety and effectiveness of the device . . . “[1] As can be seen, the FDA insists on the safety of the device despite the harm it had caused to thousands or perhaps millions of women worldwide. In doing so, the FDA clearly neglects the well established medical principle of nil nocere which stipulates treatment of the patient without causing harm to her/his heath. The FDA’s emphasis on the safety of a device that has caused serious harm brings to light also a problem that is frequently encountered in the scientific literature, namely the disregard for the parameter safety. By arguing that “the benefits outweigh the risks,” the problem of safety is frequently belittled. [5] As a consequence, women recognize that they cannot count on information even if it emanates from the most influential organization. Unfortunately unreliable information disseminated by influential organization is not the only problem. An additional problem is the information provided by manufacturers on their products, a problem recently elucidated in the area of pharmaceutico-vigilance. [6] Thus in conjunction with the harmful device for permanent contraception, the National Center for Health Research criticized information provided by the manufacturer as being too long, technical and confusing: “How many people do you know who would carefully read a 22-page document before signing it?” said Diana Zuckerman, president of the National Center for Health Research, a consumer advocacy group. “In addition to being much too long and technical, the information provided will be confusing to many consumers.”[1] In addition to flawed information furnished my manufacturers, there is an additional problem...
for women in search or reliable information, namely discordant statements in the scientific literature. It is particularly deplorable that it is just precisely the most effective methods of contraception, [7] namely Long-Acting Reversible contraception (LARC), on for which contradictory statements are made in the most prestigious scientific journals. One of the most striking examples of contradictory claims is evidence-based critique of traditional devices voiced by Belgian authors on the one hand, [8] and total disregard of this critique by US authors on the other.[9]

As early as 2013 Belgian authors described a new device, designated “Gynefix,” which was designed to remedy the deficits of the hitherto available devices.[10] The critique of the “conventional” devices, ie, ParaGard and Mirena, approved for and distributed on the US market seems convincing as it is the result of evidence-based research on measurements of the uterine cavity and on the inappropriate dimensions of the conventional devices.[8] Interestingly enough, this critique has been neglected by the authors of one of the most pertinent publications on Long-Acting Reversible Contraception (LARC), which appeared in 2017 in one of the world’s leading medical journals.[9] These authors hail LARC justifiably as the most effective methods of contraception, but ignore the evidence-based findings described in the 2013 publication. Indeed, there is no discussion of the shortcomings attributed to conventional LARCs; GyneFix is not even mentioned as one of the devices belonging to LARC; and references regarding the publications on GyneFix are untraceable. Instead, the authors of the 2017 publication hail precisely those LARC devices that have been considered inappropriate in the publication of 2013. LARCs are recommended not only by virtue of their high effectiveness and safety but also owing to their noteworthy rate of continuation. Without paying heed to the critique of the Belgian authors regarding the harmful effects of “conventional” devices, the US authors conclude: “All adolescents and adult women should be informed about the availability of LARC methods, given their extremely high effectiveness, safety, and high rate of continuation.”[9, p.467]

In the face of such discordant findings women will be reluctant to rely on recommendations made in the scientific literature. Indeed educated consumers are keenly aware of the problem of conflicts of interest which is increasingly plaguing scholarly publications.[9] Instead of impartial assessments the reader of these publications finds unverifiable statements endorsing the interests of the pharmaceutical company from which the authors receive grants, stipends, scholarships, and similar financial incentives. It should be noted in this context that authors publishing in Japanese journals undergo a more serious scrutiny concerning conflicting interests than those publishing in US-, European-, or Australasian journals.

2. RESULTS

As the above discussion shows, counseling for women in search of suitable methods for birth control and contraception is urgently needed especially in light of new pills and devices developed by pharmaceutical companies and available for the consumer on the market in most countries around the globe. Counseling should focus on the numerous adverse events, potential complications, and risks associated with contraceptive products. As past experience shows, serious consequences of these products have been brought to light by research in pharmacovigilance. Among these consequences are leukemia in children of mothers who have taken oral contraceptive pills,[11] depression and even suicidal action in association with certain pills for contraception,[12] the possibility of glaucoma causally related to hormonal contraception,[13] and a heightened risk of breast cancer for women taking oral contraceptives.[14] In addition a serious impact on the quality of life owing to oral contraceptive pills has been described.[15] In view of such detrimental consequences of uncritical use of contraceptive methods, physicians are challenged to pay heightened attention to appropriate counseling despite the pressure of economic maxims emphasizing such parameters as cost efficiency.[16] To facilitate their counseling obligations, suitable instruments such as the Synoptic Contraceptive Overview – based on the most reliable sources, namely Contraceptive Failure Table of 2011,[17] the WHO list of 2016,[18] and the FDA survey of 2013[19] -- will prove helpful. As this instrument can be easily used by women themselves, future common pursuits to identify the personally most suitable method of contraception should be more satisfying for
both, physicians and women, and reduce the danger of suffering harm due to the employment of inappropriate products for birth control and contraception.

3. CONCLUSION AND IMPLICATIONS

As the above analysis shows, women in search of the personally most suitable contraceptive method are frequently left out in the cold. They have to cope with the problem of how to obtain information that is not only accurate and complete but also trustworthy and reliable. In order to enable women to remedy the lack of counseling, autodidactic strategies are recommended based on such instruments as the Synoptic Contraception Overview (SCO). Utilization of this table not only assists women in identifying the personally most suitable method but spares also physicians the time-consuming efforts of accessing pertinent information by means of scholarly publications or manufacturers’ product descriptions.

REFERENCES

[1] Washington Post, April 11, 2018. Https://www.washingtonpost.com/.../2018/...sales-of-essure-birth....html.
[2] Code of Medical Ethics. Current Opinions (1992) American Medical Association. Chicago, Illinois.
[3] Kraetschmer K. Are women denied the right of self-decision? Saarbrücken: Scholars' Press, 2017.
[4] The Guardian. Mon 13 Aug 2018 01.40 BST Last modified on Mon 13 Aug 2018 02.55 BST. Https://www.theguardian.com/.../2018/.../3611534172665/13.08.2018.
[5] Kraetschmer K. Safety of Birth Control and Contraception: Pharmaceutical Companies on the Testing Bench. LOJ Pharr & Cli Res 1(4)-2019:80-86. LOJPCR.MS.ID.000116. DOI: 10.32474/LOJPCR.2019.01.000116.
[6] Kraetschmer K. Recent findings in pharmacovigilance and pharmaeuticovigilance. In press.
[7] Trussell J. Contraceptive efficacy. Table 3-2. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011. CTFailure. Table.pdf.
[8] Wildemeersch D, Pett A, Jandl S, Hasskamp T,Rowe P, Vrijens M. Precision intrauterine contraception may significantly increase continuation of use: a review of long-term clinical experience with frameless copper-releasing intrauterine contraception devices. Int J Womens Health. 2013; 5: 215–225. Published online 2013 Apr 30. doi: 10.2147/IJWH.S42784PMCID: PMC3645905. PMID: 23658502.
[9] Curtis KM, Peipert JF. Long-Acting Reversible Contraception. N Engl J Med 2017; 376:461-8. DOI: 10.1056/NEJMcp1608736.
[10] GynFix. CONTREL Manufacturer Information for the user. CONTREL EUROPE Incubation - en innovatiecentrum, Technologiepark 3 B1 (Universiteit Gent), 9052 Gent (Zwijnaarde).
[11] Hargrave M, Morch LS, Andersen KK, Winther JF. Schmiegelow K, Kjaer SK. Maternal use of hormonal contraception and risk of childhood leukaemia – Authors’ reply. Maternal use of hormonal contraception and risk of childhood leukaemia. The Lancet Oncology. Correspondence. Volume 19, Issue 12, P659, December 01, 2018. DOI: https://doi.org/10.1016/S1470-2045(18)30849-0.
[12] European Medicines Agency. Science Medicines Health. 29 October 2018. EMA/PRAC/689235/2018. Pharmacovigilance Risk Assessment Committee (PRAC).
[13] Bhanwra S, Ahuwalia K. The association of oral contraceptive pills with increase in intraocular pressure: Time for pharmacovigilance to step in. Journal of Pharmacology and Pharmacotherapeutics. 6(1):51. January 2015 with 14 Reads. DOI: 10.4103/0976-600X.149150. Http://www.jpharmacol.com on Wednesday, September 28, 2016, IP: 195.240.6.86.
[14] Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lieggaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. n engl j med 377; 23 nejm.org December 7, 2017.
[15] Zethraeus N, Dreber A, Ranehill E, Blomberg L, Labrie F, Schoutz B, Johnnesson M, Lindén Hirschberg. A first choice combined oral contraceptive influences general well-being in healthy women. Fertility and Sterility, online 18 April 2017. doi: 10.1016/j.fertnstert.2017.02.120. Available at: ki.sel.../oral-contraceptives-reduce-general-well-being-in healthy-women.
[16] Kraetschmer K. Is the “lege artis” principle obsolete? J Forensic Res. 2013; 4:3.
[17] CTFailure.Table.pdf Available at: www.contraceptivetechnology.org/the-book/take-a-peek/contraceptive-effficacy.). (Accessed August 27, 2016). In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011. CTFailure. Table.pdf.
[18] World Health Organization (WHO).2017. Effectiveness to prevent pregnancy. Accessed on Nov 20, 2019 at: https://www.who.int/news-room/fact-sheets/detail/family-planning-
contraception.

[19] U.S. Food and Drug Association (FDA) Survey of 2013 Food and Drug Administration (FDA) Approved Methods of Birth Control http://www.fad.gov/ForConsumers/ByAudience/ForWomen/FreePublications/ucm313215.htm.) (Accessed January 16, 2017).